Cerebrovascular Diseases
Original Paper
Effect of Prothrombin Complex Concentrate on Hematoma Enlargement and Clinical Outcome in Patients with Anticoagulant-Associated Intracerebral HemorrhageKuwashiro T.a · Yasaka M.a, b · Itabashi R.a · Nakagaki H.a · Miyashita F.a · Naritomi H.a · Minematsu K.aaDepartment of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, and bDepartment of Cerebrovascular Disease, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: May 06, 2010
Accepted: September 27, 2010
Published online: December 03, 2010
Issue release date: January 2011
Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 5
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Abstract
Background: The present study was carried out to determine the effect of prothrombin complex concentrate (PCC) on hematoma enlargement (HE) and the early clinical outcome of intracerebral hemorrhage (ICH) patients on long-term warfarin treatment. Methods: Themedical records and computed tomography (CT) images of 50 consecutive ICH patients on long-term warfarin treatment (35 men, 15 women; 69 ± 12 years old) were reviewed. International normalized ratio (INR) values, frequency of HE and clinical outcome were compared between patients treated with and without PCC. Results: INR values on admission were above 2.0 in 37 patients, of whom 19 were given PCC (PCC group) and 18 were not given PCC (control group). In these 37 patients, the frequency of HE (p = 0.017), the number of patients with a poor clinical outcome (modified Rankin Scale score ≧3 at 30 days or at discharge; p = 0.045) and in-hospital mortality (p = 0.042) were significantly higher in the control than in the PCC group. On multivariate logistic regression analysis with adjustment, PCC administration was independently associated (odds ratio 0.03, 95% confidence interval 0.00–0.63; p = 0.023) with a reduction in poor clinical outcome in ICH patients whose INR values were >2.0 on admission. Conclusions: Immediate INR reversal with PCC may prevent HE and subsequent poor outcome.
© 2010 S. Karger AG, Basel
Related Articles:
References
- Wintzen AR, de Jonge H, Loeliger EA, Bots GT: The risk of intracerebral hemorrhage during oral anticoagulant treatment: a population study. Ann Neurol 1984;16:553–558.
- Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM: The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880–884.
- Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J: Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology 2004;63:1059–1064.
- Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, Mueller S, Meyding-Lamade U, Strobl R, Mansmann U, Schwab S, Steiner T: Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke 2006;37:1465–1470.
- Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T; Recombinant Activated Factor VII Intracerebral Hemorrhage Trial Investigators: Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology 2006;66:1175–1181.
- Kuwashiro T, Yasaka M, Itabashi R, Nakagaki H, Miyashita F, Naritomi H, Minematsu K: Enlargement of acute intracerebral hematomas in patients on long-term warfarin treatment. Cerebrovasc Dis 2010;29:446–453.
- Toyoda K, Yasaka M, Nagata K, Nagao T, Gotoh J, Sakamoto T, Uchiyama S, Minematsu K; Bleeding with Antithrombotic Therapy Study Group: Antithrombotic therapy influences location, enlargement, and mortality from intracerebral hemorrhage. The Bleeding with Antithrombotic Therapy (BAT) Retrospective Study. Cerebrovasc Dis 2009;27:151–159.
- Hannon N, Sheehan O, Kelly L, Marnane M, Merwick A, Moore A, Kyne L, Duggan J, Moroney J, McCormack PM, Daly L, Fitz-Simon N, Harris D, Horgan G, Williams EB, Furie KL, Kelly PJ: Stroke associated with atrial fibrillation – incidence and early outcomes in the north Dublin Population Stroke Study. Cerebrovasc Dis 2010;29:43–49.
- Boulis NM, Bobek MP, Schmaier A, Hoff JT: Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 1999;45:1113–1119.
- Cartmill M, Dolan G, Byrne JL, Byrne PO: Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergency. Br J Neurosurg 2000;14:458–461.
- Fredriksson K, Norrving B, Sttomblad LG: Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 1992;23:972–977.
- Makris M, Graves M, Phillips WS, Kitchen S, Rosendaal FR: Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 1997;77:477–480.
- Siddiq F, Jalil A, McDaniel C, Brock DG, Pineda CC, Bell RD, Lee K: Effectiveness of factor IX complex concentrate in reversing warfarin associated coagulopathy for intracerebral hemorrhage.Neurocrit Care 2008;8:36–41.
- Yasaka M, Minematsu K, Naritomi H, Sakata T, Yamaguchi T: Predisposing factors for enlargement of intracerebral hemorrhage in patients treated with warfarin. Thromb Haemost 2003;89:278–283.
-
Yasaka M, Sakata T, Minematsu K, Naritomi H: Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res 2003;108:25–30.
External Resources
- Yasaka M, Sakata T, Naritomi H, Minematsu K: Optimal dose of prothrombin complex concentrate for acute reversal of oral anticoagulation. Thromb Res 2005;115:455–459.
- Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J: The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996;27:1304–1305.
- Huttner HB, Steiner T, Hartmann M, Köhrmann M, Juettler E, Mueller S, Wikner J, Meyding-Lamade U, Schramm P, Schwab S, Schellinger PD: Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage. Stroke 2006;37:404–408.
- Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G: Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke 1993;24:987–993.
- Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF: Spontaneous intracerebral hemorrhage. N Engl J Med 2001;344:1450–1460.
- Kazui S, Naritomi H, Yamamoto H, Sawada T, Yamaguchi T: Enlargement of spontaneous intracerebral hemorrhage. Incidence and time course. Stroke 1996;27:1783–1787.
- van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J: Interobserver agreement for assessment of handicap in stroke patients. Stroke 1988;19:604–607.
- Lisk DR, Pasteur W, Rhoades H, Putnam RD, Grotta JC: Early presentation of hemispheric intracerebral hemorrhage: prediction of outcome and guidelines for treatment allocation. Neurology 1994;44:133–139.
- Flaherty ML, Tao H, Haverbusch M, Sekar P, Kleindorfer D, Kissela B, Khatri P, Stettler B, Adeoye O, Moomaw CJ, Broderick JP, Woo D: Warfarin use leads to larger intracerebral hematomas. Neurology 2008;71:1084–1089.
- Kazui S, Minematsu K, Yamamoto H, Sawada T, Yamaguchi T: Predisposing factors to enlargement of spontaneous intracerebral hematoma. Stroke 1997;28:2370–2375.
- Kawamata T, Takeshita M, Kubo O, Izawa M, Kagawa M, Takakura K: Management of intracranial hemorrhage associated with anticoagulant therapy. Surg Neurol 1995;44:438–443.
- Ohwaki K, Yano E, Nagashima H, Hirata M, Nakagomi T, Tamura A: Blood pressure management in acute intracerebral hemorrhage: relationship between elevated blood pressure and hematoma enlargement. Stroke 2004;35:1364–1367.
Article / Publication Details
Received: May 06, 2010
Accepted: September 27, 2010
Published online: December 03, 2010
Issue release date: January 2011
Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 5
ISSN: 1015-9770 (Print)
eISSN: 1421-9786 (Online)
For additional information: https://www.karger.com/CED
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
